 |
|
|
|
 |
|
|
| Article 1 to 5 out of 5 concerning DxS Ltd
|
-
Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests
(06/04/2008)
Tests identify genetic mutations that can affect patient response to certain cancer drugs
Roche and DxS Ltd. have signed an exclusive distribution agreement for the DxS TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test. The tests are intended, when considered with other clinically relevant factors, to aid doctors in ...
-
DxS Announces Plans to Expand its Manufacturing Capacity
(05/27/2008)
Company also announces Award of ISO 13485 certification
DxS has announced plans to expand its manufacturing facilities, and to significantly increase the number of staff. In addition, the Company has also been awarded the ISO 13485:2003 quality certification for the "design, development and manufacture ...
-
Epigenomics and DxS Enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions Technology in DNA Methylation
(01/15/2008)
Epigenomics AG (and DxS Ltd. announced that they have entered into a strategic cross-licensing agreement. Under the terms of the agreement, Epigenomics obtains worldwide non-exclusive rights to DxS' proprietary ScorpionsŪ technology for R&D use and ...
-
DxS receives Biotechnology Award for Cancer product from BioNow
(11/30/2006)
DxS has won a 'Biotechnology Project of the Year' award for its highly sensitive EGFR (Epidermal Growth Factor Receptor) Mutation Test Kit. Sponsored by the Manchester based law firm Pannone LLP, the award was presented by Bionow, the Northwest ...
-
Genetic Mutation Assay Brings Personalised Cancer Treatment One-Step Closer
(06/14/2004)
Dia. DxS Ltd, the Manchester (UK) based personalised medicine company, announced today that it had taken a step closer to its goal of improving drug therapy by developing a diagnostic test which predicts response to anti-cancer drugs. This follows ...
Additional information
DxS Ltd
Manchester, United Kingdom
Company
|
|
|
|
|
|
Top
